Sagimet Biosciences (SGMT) Expected to Announce Earnings on Thursday

Sagimet Biosciences (NASDAQ:SGMT) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Sagimet Biosciences to post earnings of ($0.39) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last posted its quarterly earnings results on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. On average, analysts expect Sagimet Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sagimet Biosciences Trading Down 0.3%

NASDAQ SGMT opened at $7.69 on Tuesday. The firm’s fifty day moving average price is $5.90 and its two-hundred day moving average price is $6.28. Sagimet Biosciences has a 1 year low of $3.08 and a 1 year high of $11.41. The firm has a market capitalization of $250.54 million, a P/E ratio of -4.90 and a beta of 3.60.

Hedge Funds Weigh In On Sagimet Biosciences

Large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in shares of Sagimet Biosciences by 819.2% in the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares during the period. Bank of America Corp DE grew its stake in shares of Sagimet Biosciences by 81.8% in the second quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock valued at $76,000 after acquiring an additional 4,473 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Sagimet Biosciences in the fourth quarter valued at about $62,000. Jefferies Financial Group Inc. acquired a new position in shares of Sagimet Biosciences in the third quarter valued at about $95,000. Finally, LPL Financial LLC grew its stake in shares of Sagimet Biosciences by 31.3% in the fourth quarter. LPL Financial LLC now owns 20,574 shares of the company’s stock valued at $122,000 after acquiring an additional 4,899 shares in the last quarter. 87.86% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Sagimet Biosciences in a research report on Friday, May 1st. Barclays began coverage on shares of Sagimet Biosciences in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price target on the stock. Canaccord Genuity Group increased their price objective on shares of Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Wall Street Zen raised shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Rodman & Renshaw began coverage on shares of Sagimet Biosciences in a research report on Thursday, March 26th. They issued a “buy” rating and a $28.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sagimet Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $28.63.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.